Corvus Pharmaceuticals Inc

1
NAS:CRVS (USA)  
$ 1.82 +0.03 (+1.68%) 12:02 PM EST
At Loss
P/B:
2.30
Market Cap:
$ 89.25M
Enterprise V:
$ 62.00M
Volume:
181.52K
Avg Vol (2M):
215.32K
Also Trade In:
Volume:
181.52K
At Loss
Avg Vol (2M):
215.32K

Business Description

Description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's main product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
Name Current Vs Industry Vs History
Cash-To-Debt 19.76
Equity-to-Asset 0.85
Debt-to-Equity 0.04
Debt-to-EBITDA -0.06
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 31.9
9-Day RSI 31.13
14-Day RSI 34.89
6-1 Month Momentum % 62.76
12-1 Month Momentum % 263.08

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.07
Quick Ratio 4.07
Cash Ratio 3.95

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -20
Shareholder Yield % 1.34
Name Current Vs Industry Vs History
ROE % -56.92
ROA % -47.93
ROIC % -101.34
ROC (Joel Greenblatt) % -1180.98
ROCE % -48.58

Financials (Next Earnings Date:2024-05-08 Est.)

CRVS's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CRVS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Corvus Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.56
Beta 0.22
Volatility % 192.52
14-Day RSI 34.89
14-Day ATR ($) 0.145959
20-Day SMA ($) 1.985
12-1 Month Momentum % 263.08
52-Week Range ($) 0.66 - 4.19
Shares Outstanding (Mil) 49.04

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Corvus Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Corvus Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Corvus Pharmaceuticals Inc Frequently Asked Questions

What is Corvus Pharmaceuticals Inc(CRVS)'s stock price today?
The current price of CRVS is $1.82. The 52 week high of CRVS is $4.19 and 52 week low is $0.66.
When is next earnings date of Corvus Pharmaceuticals Inc(CRVS)?
The next earnings date of Corvus Pharmaceuticals Inc(CRVS) is 2024-05-08 Est..
Does Corvus Pharmaceuticals Inc(CRVS) pay dividends? If so, how much?
Corvus Pharmaceuticals Inc(CRVS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1